Cargando…

Efficacy of PI monotherapy versus triple therapy for 1964 patients in 10 randomised trials

INTRODUCTION: The efficacy of protease inhibitor monotherapy has been analyzed with different endpoints: initial HIV-1 RNA rebound, long-term HIV-1 RNA suppression after re-intensification, treatment-emergent drug resistance, neurocognitive testing and HIV-1 RNA in the cerebrospinal fluid (CSF). MET...

Descripción completa

Detalles Bibliográficos
Autores principales:	Arribas, Jose, Girard, Pierre-Marie, Paton, Nicholas, Winston, Alan, Marcelin, Anne-Genevieve, Elbirt, Daniel, Hill, Andrew, Blanca Hadacek, Maria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International AIDS Society 2014
Materias:	Poster Sessions – Abstract P256
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225292/ https://www.ncbi.nlm.nih.gov/pubmed/25397532 http://dx.doi.org/10.7448/IAS.17.4.19788

Ejemplares similares

Circulating Exosomes from Human Lung Transplant Recipients Having Respiratory Viral Infections Contain Nucleic Acids and Activate Signaling Pathways CGAS/STING and RIG-1
por: Bansal, S., et al.
Publicado: (2020)

Using Donor-Derived Cell-Free DNA for Assessment of Myocardial Injury in Heart Transplant Recipients After SARS-CoV2 Infection
por: Kamath, M., et al.
Publicado: (2022)

Impact de la corticothérapie systémique sur les séquelles respiratoires des infections à SARS-CoV-2
por: Delomez, J., et al.
Publicado: (2022)

Cerebral volumes, neuronal integrity and brain inflammation measured by MRI in patients receiving PI monotherapy or triple therapy
por: Pérez Valero, Ignacio, et al.
Publicado: (2014)

Less frequent follow-up in routine care than in trials does not impact resistance selection in patients failing DRV/r or ATV/r first line treatment
por: Marcelin, Anne-Genevieve, et al.
Publicado: (2014)

Randomized trial of DRV/r or LPV/r QD monotherapy vs maintaining a PI/r-based antiretroviral regimen in persons with suppressed HIV replication
por: Pinnetti, Carmela, et al.
Publicado: (2014)

Monotherapy with darunavir/ritonavir is effective and safe in clinical practice
por: Pasquau, Juan, et al.
Publicado: (2014)

Changes in lipid levels after 48 weeks of dual versus triple therapy observed in the GARDEL study
por: Cahn, Pedro, et al.
Publicado: (2014)

Simplification to Stribild vs continuation of RTV-boosted DRV with FTC and TDF in virologically suppressed HIV adults: a STRATEGY-PI subgroup analysis
por: Arribas, Jose, et al.
Publicado: (2014)

Resistance mutations in protease gene at baseline are not related to virological failure in patients treated with darunavir/ritonavir monotherapy
por: Gutierrez-Liarte, Angela, et al.
Publicado: (2014)

CSF LPV concentrations and viral load in viral suppressed patients on LPV/r monotherapy given once daily
por: Tiraboschi, Juan, et al.
Publicado: (2014)

Atazanavir/ritonavir monotherapy as maintenance strategy in HIV-1 treated subjects with viral suppression: 96-week analysis results of the MODAT study
por: Spagnuolo, Vincenzo, et al.
Publicado: (2014)

Lamivudine monotherapy as a safe option for HIV-infected paediatric clients with adherence challenges: new evidence from a large South African cohort
por: Linder, Verena, et al.
Publicado: (2014)

The state of PI monotherapy and NRTI-sparing therapy
por: Arribas, JR
Publicado: (2010)

Vaccination contre le SARS-CoV-2 avant l’introduction d’un traitement par anti-CD20 chez les patients atteints de sclérose en plaques : une protection durable ?
por: Jeantin, Lina, et al.
Publicado: (2023)

Efficacy and tolerability of telaprevir (TVR)-based triple therapy in HIV/HCV-coinfected patients
por: De Los Santos, Ignacio, et al.
Publicado: (2014)

Potential implications of CYP3A4, CYP3A5 and MDR-1 genetic variants on the efficacy of Lopinavir/Ritonavir (LPV/r) monotherapy in HIV-1 patients
por: Berno, Giulia, et al.
Publicado: (2014)

Cost/efficacy analysis of preferred Spanish AIDS study group regimens and the dual therapy with LPV/r+3TC for initial ART in HIV infected adults
por: Gatell, Josép M, et al.
Publicado: (2014)

HCV triple therapy in co-infection HIV/HCV is not associated with a different risk of developing major depressive disorder
por: Fialho, Renata, et al.
Publicado: (2014)

Nephrolithiasis and renal failure among patients exposed to atazanavir, other PIs and PI-free regimens
por: Nkhoma, Ella, et al.
Publicado: (2014)

Renal safety profile of STB in virologically suppressed subjects from two randomized phase 3b switch trials
por: Reeves, Iain, et al.
Publicado: (2014)

Facial emotional processing deficits in long-term HIV-suppressed patients
por: Gonzalez-Baeza, Alicia, et al.
Publicado: (2014)

Cerebrospinal-fluid exposure of efavirenz and its major metabolites when dosed at 400 and 600 mg once daily; a randomized controlled trial
por: Winston, Alan, et al.
Publicado: (2014)

Zona après vaccination anti-COVID-19 : série descriptive de 10 cas
por: Massip, Edouard, et al.
Publicado: (2021)

Simulation of the impact of rifampicin on darunavir/ritonavir PK and dose adjustment strategies in HIV-infected patients: a population PK approach
por: Dickinson, Laura, et al.
Publicado: (2014)

Impact of etravirine use on hospitalization rates among highly pre-treated failing HIV-1 infected individuals between 2005 and 2011
por: Lacombe, Jean-Marc, et al.
Publicado: (2014)

Intermittent viraemia and immune reconstitution in patients with more than 10–15 years of antiretroviral therapy: baseline values still matter
por: Erdbeer, Gesa, et al.
Publicado: (2014)

Acute hepatitis C virus (HCV) infection in the setting of HIV coinfection: a single-centre 10-year follow-up
por: Ingiliz, Patrick, et al.
Publicado: (2014)

Telaprevir combination therapy in HCV/HIV co-infected patients (INSIGHT study): sustained virologic response at 12 weeks final analysis
por: Montes, Marisa, et al.
Publicado: (2014)

Long-term efficacy and safety of E/C/F/TDF vs EFV/FTC/TDF and ATV+RTV+FTC/TDF in HIV-1-infected treatment-naïve subjects ≥50 years
por: Gazzard, Brian, et al.
Publicado: (2014)

Efficacy of a reduced dose of DARUNAVIR/RTV in a cohort of antiretroviral-naïve and experienced HIV-infected patients: a medium-term follow-up
por: Lanzafame, Massimiliano, et al.
Publicado: (2014)

Should the dose of tenofovir be reduced to 200–250 mg/day, when combined with protease inhibitors?
por: Hill, Andrew, et al.
Publicado: (2014)

Prices of second-line antiretroviral treatment for middle-income countries inside versus outside sub-Saharan Africa
por: Simmons, Bryony, et al.
Publicado: (2014)

Absence de relation directe entre l’épidémie récente d’engelures et l’infection par le SARS-CoV-2 : étude virologique de 10 cas consécutifs
por: Rouanet, J., et al.
Publicado: (2020)

Impact of NRTI backbone on renal, bone and cardiovascular markers in HIV-infected individuals receiving a boosted protease inhibitor
por: Barber, Tristan, et al.
Publicado: (2014)

Effect of hyperbilirubinaemia on neurocognitive, renal, bone and cardiovascular markers in HIV infection treated with boosted protease inhibitors
por: Barber, Tristan J, et al.
Publicado: (2014)

Analysis of major and minor IAS-USA PI mutations in the MONET trial of darunavir/ritonavir monotherapy versus DRV/r + 2NRTIs
por: Pulido, F, et al.
Publicado: (2010)

CERN Courier Volume 4, Number 10, October 1964
por: CERN
Publicado: (1964)

Courrier CERN Volume 4, N° 10, Octobre 1964
por: CERN
Publicado: (1964)

S213: BMS-986158, A POTENT BET INHIBITOR, AS MONOTHERAPY AND IN COMBINATION WITH RUXOLITINIB OR FEDRATINIB IN INTERMEDIATE- OR HIGH-RISK MYELOFIBROSIS (MF): RESULTS FROM A PHASE 1/2 STUDY
por: Ayala, Rosa, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_rd5dfvrdt93j2387tdrnbf50sc